Have a personal or library account? Click to login
Sarcopenic obesity in cancer Cover
Open Access
|Feb 2024

References

  1. Baumgartner RN. Body composition in healthy aging. Ann N Y Acad Sci 2000; 904: 437–48. doi: <a href="https://doi.org/10.1111/j.1749-6632.2000.tb06498.x" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1111/j.1749-6632.2000.tb06498.x</a>
  2. Barazzoni R, Bischoff SC, Boirie Y, Busetto L, Cederholm T, Dicker D, et al. Sarcopenic obesity: Time to meet the challenge. Clin Nutr 2018; 37(6 Pt A): 1787–93. doi: <a href="https://doi.org/10.1016/j.clnu.2018.04.018" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.clnu.2018.04.018</a>
  3. Gao Q, Mei F, Shang Y, Hu K, Chen F, Zhao L, et al. Global prevalence of sarcopenic obesity in older adults: a systematic review and meta-analysis. Clin Nutr 2021; 40: 4633–41. doi: <a href="https://doi.org/10.1016/j.clnu.2021.06.009" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.clnu.2021.06.009</a>
  4. Gao Q, Hu K, Gao J, Shang Y, Mei F, Zhao L, et al. Prevalence and prognostic value of sarcopenic obesity in patients with cancer: a systematic review and meta-analysis. Nutrition 2022; 101: 111704. doi: <a href="https://doi.org/10.1016/j.nut.2022.111704" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.nut.2022.111704</a>
  5. Gortan Cappellari G, Brasacchio C, Laudisio D, Lubrano C, Pivari F, Barrea L, et al. Sarcopenic obesity: what about in the cancer setting? Nutrition 2022; 98: 111624. doi: <a href="https://doi.org/10.1016/j.nut.2022.111624" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.nut.2022.111624</a>
  6. Carneiro IP, Mazurak VC, Prado CM. Clinical implications of sarcopenic obesity in cancer. Curr Oncol Rep 2016; 18: 62. doi: <a href="https://doi.org/10.1007/s11912-016-0546-5" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s11912-016-0546-5</a>
  7. Atkins JL, Wannamathee SG. Sarcopenic obesity in ageing: cardiovascular outcomes and mortality. Br J Nutr 2020; 124: 1102–13. doi: <a href="https://doi.org/10.1017/S0007114520002172" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1017/S0007114520002172</a>
  8. Silveira EA, da Silva Filho RR, Spexoto MCB, Haghighatdoost F, Sarrafzadegan N, de Oliveira C. The role of sarcopenic obesity in cancer and cardiovascular disease: a synthesis of the evidence on pathophysiological aspects and clinical implications. Int J Mol Sci 2021; 22: 4339. doi: <a href="https://doi.org/10.3390/ijms22094339" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3390/ijms22094339</a>
  9. Donini LM, Busetto L, Bischoff SC, Cederholm T, Ballesteros-Pomar MD, Batsis JA, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Obes Facts 2022; 15: 321–35. doi: <a href="https://doi.org/10.1159/000521241" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1159/000521241</a>
  10. Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol 2018; 14: 513–37. doi: <a href="https://doi.org/10.1038/s41574-018-0062-9" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/s41574-018-0062-9</a>
  11. Chargi N, Bril SI, Swartz JE, Wegner I, Willems SM, de Bree R. Skeletal muscle mass is an imaging biomarker for decreased survival in patients with oropharyngeal squamous cell carcinoma. Oral Oncol 2020; 101: 104519. doi: <a href="https://doi.org/10.1016/j.oraloncology.2019.104519" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.oraloncology.2019.104519</a>
  12. Kiss N, Beraldo J, Everitt S. Early skeletal muscle loss in non-small cell lung cancer patients receiving chemoradiation and relationship to survival. Support Care Cancer 2019; 27: 2657–64. doi: <a href="https://doi.org/10.1007/s00520-018-4563-9" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s00520-018-4563-9</a>
  13. Recio-Boiles A, Galeas JN, Goldwasser B, Sanchez K, Man LMW, Gentzler RD, et al. Enhancing evaluation of sarcopenia in patients with non-small cell lung cancer (NSCLC) by assessing skeletal muscle index (SMI) at the first lumbar (L1) level on routine chest computed tomography (CT). Support Care Cancer 2018; 26: 2353–59. doi: <a href="https://doi.org/10.1007/s00520-018-4051-2" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s00520-018-4051-2</a>
  14. Lodewick TM, van Nijnatten TJ, van Dam RM, van Mierlo K, Dello SA, Neumann UP, et al. Are sarcopenia, obesity and sarcopenic obesity predictive of outcome in patients with colorectal liver metastases? HPB (Oxford) 2015; 17: 438–46. doi: <a href="https://doi.org/10.1111/hpb.12373" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1111/hpb.12373</a>
  15. Grotenhuis BA, Shapiro J, van Adrichem S, de Vries M, Koek M, Wijnhoven BP, et al. Sarcopenia/muscle mass is not a prognostic factor for short- and long-term outcome after esophagectomy for cancer. World J Surg 2016; 40: 2698–704. doi: <a href="https://doi.org/10.1007/s00268-016-3603-1" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s00268-016-3603-1</a>
  16. Kim YM, Kim JH, Baik SJ, Chun J, Youn YH, Park H. Sarcopenia and sarcopenic obesity as novel risk factors for gastric carcinogenesis: a health checkup cohort study. Front Oncol 2019; 9: 1249. doi: <a href="https://doi.org/10.3389/fonc.2019.01249" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3389/fonc.2019.01249</a>
  17. Lou N, Chi CH, Chen XD, Zhou CJ, Wang SL, Zhuang CL, et al. Sarcopenia in overweight and obese patients is a predictive factor for postoperative complication in gastric cancer: a prospective study. Eur J Surg Oncol 2017; 43: 188–95. doi: <a href="https://doi.org/10.1016/j.ejso.2016.09.006" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ejso.2016.09.006</a>
  18. Nishigori T, Tsunoda S, Okabe H, Tanaka E, Hisamori S, Hosogi H, et al. Impact of sarcopenic obesity on surgical site infection after laparoscopic total gastrectomy. Ann Surg Oncol 2016; 23(Suppl 4): 524–31. doi: <a href="https://doi.org/10.1245/s10434-016-5385-y" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1245/s10434-016-5385-y</a>
  19. Palmela C, Velho S, Agostinho L, Branco F, Santos M, Santos MP, et al. Body composition as a prognostic factor of neoadjuvant chemotherapy toxicity and outcome in patients with locally advanced gastric cancer. J Gastric Cancer 2017; 17: 74–87. doi: <a href="https://doi.org/10.5230/jgc.2017.17.e8" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.5230/jgc.2017.17.e8</a>
  20. Sugawara K, Yamashita H, Okumura Y, Yagi K, Yoshimura S, Kawasaki K, et al. Relationships among body composition, muscle strength, and sarcopenia in esophageal squamous cell carcinoma patients. Support Care Cancer 2020; 28: 2797–803. doi: <a href="https://doi.org/10.1007/s00520-019-05110-7" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s00520-019-05110-7</a>
  21. Zhang WT, Lin J, Chen WS, Huang YS, Wu RS, Chen XD, et al. Sarcopenic obesity is associated with severe postoperative complications in gastric cancer patients undergoing gastrectomy: a prospective study. J Gastrointest Surg 2018; 22: 1861–69. doi: <a href="https://doi.org/10.1007/s11605-018-3835-5" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s11605-018-3835-5</a>
  22. Giani A, Famularo S, Riva L, Tamini N, Ippolito D, Nespoli L, et al. Association between specific presurgical anthropometric indexes and morbidity in patients undergoing rectal cancer resection. Nutrition. 2020; 75–76: 110779. doi: <a href="https://doi.org/10.1016/j.nut.2020.110779" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.nut.2020.110779</a>
  23. Han JS, Ryu H, Park IJ, Kim KW, Shin Y, Kim SO, et al. Association of body composition with long-term survival in non-metastatic rectal cancer patients. Cancer Res Treat 2020; 52: 563–72. doi: <a href="https://doi.org/10.4143/crt.2019.249" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.4143/crt.2019.249</a>
  24. Malietzis G, Currie AC, Athanasiou T, Johns N, Anyamene N, Glynne-Jones R, et al. Influence of body composition profile on outcomes following colorectal cancer surgery. Br J Surg 2016; 103: 572–80. doi: <a href="https://doi.org/10.1002/bjs.10075" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/bjs.10075</a>
  25. Gruber ES, Jomrich G, Tamandl D, Gnant M, Schindl M, Sahora K. Correction: Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resecTable pancreatic ductal adenocarcinoma. PLoS One 2020; 15: e0244896. doi: <a href="https://doi.org/10.1371/journal.pone.0244896." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1371/journal.pone.0244896.</a> Erratum for: PLoS One 2019 6; 14: e0215915. doi: <a href="https://doi.org/10.1371/journal.pone.0215915" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1371/journal.pone.0215915</a>
  26. Kobayashi A, Kaido T, Hamaguchi Y, Okumura S, Shirai H, Yao S, et al. Impact of sarcopenic obesity on outcomes in patients undergoing hepatectomy for hepatocellular carcinoma. Ann Surg 2019; 269: 924–31. doi: <a href="https://doi.org/10.1097/SLA.0000000000002555" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1097/SLA.0000000000002555</a>
  27. Kimura Y, Yamada M, Ohji S, Ishiyama D, Nishio N, Otobe Y, et al. Presence of sarcopenic obesity and evaluation of the associated muscle quality in Japanese older men with prostate cancer undergoing androgen deprivation therapy. J Geriatr Oncol 2019; 10: 835–8. doi: <a href="https://doi.org/10.1016/j.jgo.2019.03.017" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.jgo.2019.03.017</a>
  28. Kocher NJ, Jafri S, Balabhadra S, Lehman E, Gardner J, Vijay K, et al. Is sarcopenia and sarcopenic obesity associated with clinical and pathological outcomes in patients undergoing radical nephroureterectomy? Urol Oncol 2018; 36: 156.e17–156.e22. doi: <a href="https://doi.org/10.1016/j.urolonc.2017.12.004" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.urolonc.2017.12.004</a>
  29. Cushen SJ, Power DG, Murphy KP, McDermott R, Griffin BT, Lim M, et al. Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel. Clin Nutr ESPEN 2016; 13: e39–45. doi: <a href="https://doi.org/10.1016/j.clnesp.2016.04.001" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.clnesp.2016.04.001</a>
  30. Rier HN, Jager A, Sleijfer S, van Rosmalen J, Kock MCJM, Levin MD. Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy. Breast 2017; 31: c9–15. doi: <a href="https://doi.org/10.1016/j.breast.2016.10.014" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.breast.2016.10.014</a>
  31. Heidelberger V, Goldwasser F, Kramkimel N, Jouinot A, Huillard O, Boudou-Rouquette P, et al. Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients. Invest New Drugs 2017; 35: 436–41. doi: <a href="https://doi.org/10.1007/s10637-017-0464-x." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s10637-017-0464-x.</a> Erratum in: Invest New Drugs 2017; 35: 537. doi: <a href="https://doi.org/10.1007/s10637-017-0475-7" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s10637-017-0475-7</a>
  32. Jabbour J, Manana B, Zahreddine A, Saade C, Charafeddine M, Bazarbachi A, et al. Sarcopenic obesity derived from PET/CT predicts mortality in lymphoma patients undergoing hematopoietic stem cell transplantation. Curr Res Transl Med 2019; 67: 93–9. doi: <a href="https://doi.org/10.1016/j.retram.2018.12.001" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.retram.2018.12.001</a>
  33. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Writing group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019; 48: 601. doi: <a href="https://doi.org/10.1093/ageing/afz046." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1093/ageing/afz046.</a> Erratum for: Age Ageing 2019; 48: 16–31. doi: <a href="https://doi.org/10.1093/ageing/afy169" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1093/ageing/afy169</a>
  34. Mei KL, Batsis JA, Mills JB, Holubar SD. Sarcopenia and sarcopenic obesity: do they predict inferior oncologic outcomes after gastrointestinal cancer surgery? Perioper Med 2016; 5: 30. doi: <a href="https://doi.org/10.1186/s13741-016-0052-1" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1186/s13741-016-0052-1</a>
  35. Prado CM, Heymsfield SB. Lean tissue imaging: a new era for nutritional assessment and intervention. JPEN J Parenter Enteral Nutr 2014; 38: 940–53. doi: <a href="https://doi.org/10.1177/0148607114550189." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1177/0148607114550189.</a> Erratum in: JPEN J Parenter Enteral Nutr 2016; 40: 742. doi: <a href="https://doi.org/10.1177/0148607116647919" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1177/0148607116647919</a>
  36. Donini LM, Busetto L, Bauer JM, Bischoff S, Boirie Y, Cederholm T, et al. Critical appraisal of definitions and diagnostic criteria for sarcopenic obesity based on a systematic review. Clin Nutr 2020; 39: 2368–88. doi: <a href="https://doi.org/10.1016/j.clnu.2019.11.024" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.clnu.2019.11.024</a>
  37. Ji T, Li Y, Ma L. Sarcopenic obesity: an emerging public health problem. Aging Dis 2022; 13: 379–88. doi: <a href="https://doi.org/10.14336/AD.2021.1006" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.14336/AD.2021.1006</a>
  38. Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol 2018; 14: 513–37. doi: <a href="https://doi.org/10.1038/s41574-018-0062-9" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/s41574-018-0062-9</a>
  39. Lynch GM, Murphy CH, Castro EM, Roche HM. Inflammation and metabolism: the role of adiposity in sarcopenic obesity. Proc Nutr Soc 2020; 16: 1–13. doi: <a href="https://doi.org/10.1017/S0029665120007119" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1017/S0029665120007119</a>
  40. Guo A, Li K, Xiao Q. Sarcopenic obesity: myokines as potential diagnostic biomarkers and therapeutic targets? Exp Gerontol 2020; 139: 111022. doi: <a href="https://doi.org/10.1016/j.exger.2020.111022" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.exger.2020.111022</a>
  41. Murton AJ, Marimuthu K, Mallinson JE, Selby AL, Smith K, Rennie MJ, et al. Obesity appears to be associated with altered muscle protein synthetic and breakdown responses to increased nutrient delivery in older men, but not reduced muscle mass or contractile function. Diabetes 2015; 64: 3160–71. doi: <a href="https://doi.org/10.2337/db15-0021" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.2337/db15-0021</a>
  42. Abbass T, Dolan RD, Laird BJ, McMillan DC. The relationship between imaging-based body composition analysis and the systemic inflammatory response in patients with cancer: A systematic review. Cancers 2019; 11: 1304. doi: <a href="https://doi.org/10.3390/cancers11091304" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3390/cancers11091304</a>
  43. Fouladiun M, Körner U, Bosaeus I, Daneryd P, Hyltander A, Lundholm KG. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care – correlations with food intake, metabolism, exercise capacity, and hormones. Cancer 2005; 103: 2189–98. doi: <a href="https://doi.org/10.1002/cncr.21013" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/cncr.21013</a>
  44. Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. Nat Rev Dis Primers 2018; 4: 17105. doi: <a href="https://doi.org/10.1038/nrdp.2017.105" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/nrdp.2017.105</a>
  45. Baracos VE, Arribas L. Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy. Ann Oncol 2018; 29(Suppl 2): ii1–9. doi: <a href="https://doi.org/10.1093/annonc/mdx810" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1093/annonc/mdx810</a>
  46. Murphy RA, Mourtzakis M, Chu QS, Reiman T, Mazurak VC. Skeletal muscle depletion is associated with reduced plasma (n-3) fatty acids in non-small cell lung cancer patients. J Nutr 2010;140: 1602–6. doi: <a href="https://doi.org/10.3945/jn.110.123521" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3945/jn.110.123521</a>
  47. Martin L, Gioulbasanis I, Senesse P, Baracos VE. Cancer-associated malnutrition and CT-defined sarcopenia and myosteatosis are endemic in over-weight and obese patients. JPEN J Parenter Enteral Nutr 2020; 44: 227–38. doi: <a href="https://doi.org/10.1002/jpen.1597" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/jpen.1597</a>
  48. Correa-de-Araujo R, Addison O, Miljkovic I, Goodpaster BH, Bergman BC, Clark RV, et al. Myosteatosis in the context of skeletal muscle function deficit: an interdisciplinary workshop at the National Institute on Aging. Front Physiol 2020; 11: 963. doi: <a href="https://doi.org/10.3389/fphys.2020.00963" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3389/fphys.2020.00963</a>
  49. Gemmink A, Goodpaster BH, Schrauwen P, Hesselink MKC. Intramyocellular lipid droplets and insulin sensitivity, the human perspective. Biochim Biophys Acta Mol Cell Biol Lipids 2017; 1862(10 Pt B): 1242–9. doi: <a href="https://doi.org/10.1016/j.bbalip.2017.07.010" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.bbalip.2017.07.010</a>
  50. Maltais A, Alméras N, Lemieux I, Tremblay A, Bergeron J, Poirier P, et al. Trunk muscle quality assessed by computed tomography: association with adiposity indices and glucose tolerance in men. Metabolism 2018; 85: 205–12. doi: <a href="https://doi.org/10.1016/j.metabol.2018.04.003" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.metabol.2018.04.003</a>
  51. Rollins KE, Tewari N, Ackner A, Awwad A, Madhusudan S, Macdonald IA, et al. The impact of sarcopenia and myosteatosis on outcomes of unresecTable pancreatic cancer or distal cholangiocarcinoma. Clin Nutr 2016; 35: 1103–9. doi: <a href="https://doi.org/10.1016/j.clnu.2015.08.005" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.clnu.2015.08.005</a>
  52. Knapp ML, al-Sheibani S, Riches PG, Hanham IW, Phillips RH. Hormonal factors associated with weight loss in patients with advanced breast cancer. Ann Clin Biochem 1991; 28 (Pt 5): 480–6. doi: <a href="https://doi.org/10.1177/000456329102800510" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1177/000456329102800510</a>
  53. Crown AL, Cottle K, Lightman SL, Falk S, Mohamed-Ali V, Armstrong L, et al. What is the role of the insulin-like growth factor system in the pathophysiology of cancer cachexia, and how is it regulated? Clin Endocrinol 2002; 56: 723–33. doi: <a href="https://doi.org/10.1046/j.1365-2265.2002.01540.x" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1046/j.1365-2265.2002.01540.x</a>
  54. Yoshikawa T, Noguchi Y, Doi C, Makino T, Nomura K. Insulin resistance in patients with cancer: relationships with tumor site, tumor stage, body-weight loss, acute-phase response, and energy expenditure. Nutrition 2001; 17: 590–3. doi: <a href="https://doi.org/10.1016/s0899-9007(01)00561-5" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/s0899-9007(01)00561-5</a>
  55. Hoffmann C, Weigert C. Skeletal muscle as an endocrine organ: the role of myokines in exercise adaptations. Cold Spring Harb Perspect Med 2017; 7: a029793. doi: <a href="https://doi.org/10.1101/cshperspect.a029793" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1101/cshperspect.a029793</a>
  56. Jurdana M. Physical activity and cancer risk. Actual knowledge and possible biological mechanisms. Radiol Oncol 2021; 55: 7–17. doi: <a href="https://doi.org/10.2478/raon-2020-0063" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.2478/raon-2020-0063</a>
  57. Rivas DA, McDonald DJ, Rice NP, Haran PH, Dolnikowski GG, Fielding RA. Diminished anabolic signaling response to insulin induced by intramuscular lipid accumulation is associated with inflammation in aging but not obesity. Am J Physiol Regul Integr Comp Physiol 2016; 310: R561–9. doi: <a href="https://doi.org/10.1152/ajpregu.00198.2015" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1152/ajpregu.00198.2015</a>
  58. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288–95. doi: <a href="https://doi.org/10.1038/nm788" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/nm788</a>
  59. Hong SH, Choi KM. Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences. Int J Mol Sci 2020; 21: 494. doi: <a href="https://doi.org/10.3390/ijms21020494" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3390/ijms21020494</a>
  60. Hamrick MW. Role of the cytokine-like hormone leptin in muscle-bone crosstalk with aging. J Bone Metab 2017; 24: 1–8. doi: <a href="https://doi.org/10.11005/jbm.2017.24.1.1" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.11005/jbm.2017.24.1.1</a>
  61. Kurdiova T, Balaz M, Vician M, Maderova D, Vlcek M, Valkovic L, et al. Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitro studies. J Physiol 2014; 592: 1091–107. doi: <a href="https://doi.org/10.1113/jphysiol.2013.264655" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1113/jphysiol.2013.264655</a>
  62. Johns N, Greig C, Fearon KC. Is tissue cross-talk important in cancer cachexia? Crit Rev Oncog 2012; 17: 263–76. doi: <a href="https://doi.org/10.1615/critrevoncog.v17.i3.40" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1615/critrevoncog.v17.i3.40</a>
  63. Argilés JM, Busquets S, Stemmler B, López-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer 2014; 14: 754–62. doi: <a href="https://doi.org/10.1038/nrc3829" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/nrc3829</a>
  64. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009; 15: 2920–6. doi: <a href="https://doi.org/10.1158/1078-0432.CCR-08-2242" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1158/1078-0432.CCR-08-2242</a>
  65. Petrelli F, Cortellini A, Indini A, Tomasello G, Ghidini M, Nigro O, et al. Association of obesity with survival outcomes in patients with cancer: a systematic review and meta-analysis. JAMA Netw Open 2021; 4: e213520 doi: <a href="https://doi.org/10.1001/jamanetworkopen.2021.3520" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1001/jamanetworkopen.2021.3520</a>
  66. Gallo M, Adinolfi V, Barucca V, Prinzi N, Renzelli V, Barrea L, et al. Expected and paradoxical effects of obesity on cancer treatment response. Rev Endocr Metab Disord 2021; 22: 681–702. doi: <a href="https://doi.org/10.1007/s11154-020-09597-y" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s11154-020-09597-y</a>
  67. Prado CM, Purcell SA, Laviano A. Nutrition interventions to treat low muscle mass in cancer. J Cachexia Sarcopenia Muscle 2020; 11: 366–80. doi: <a href="https://doi.org/10.1002/jcsm.12525" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/jcsm.12525</a>
  68. Argilés JM, Busquets S, López-Soriano FJ, Costelli P, Penna F. Are there any benefits of exercise training in cancer cachexia? J Cachexia Sarcopenia Muscle 2012; 3: 73–6. doi: <a href="https://doi.org/10.1007/s13539-012-0067-5" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s13539-012-0067-5</a>
  69. Stene GB, Helbostad JL, Balstad TR, Riphagen II, Kaasa S, Oldervoll LM. Effect of physical exercise on muscle mass and strength in cancer patients during treatment--a systematic review. Crit Rev Oncol Hematol 2013; 88: 573–93. doi: <a href="https://doi.org/10.1016/j.critrevonc.2013.07.001" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.critrevonc.2013.07.001</a>
  70. Galvão DA, Newton RU. Review of exercise intervention studies in cancer patients. J Clin Oncol 2005; 23: 899–909. doi: <a href="https://doi.org/10.1200/JCO.2005.06.085" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/JCO.2005.06.085</a>
  71. Poggiogalle E, Parrinello E, Barazzoni R, Busetto L, Donini LM. Therapeutic strategies for sarcopenic obesity: a systematic review. Curr Opin Clin Nutr Metab Care 2021; 24: 33–41. doi: <a href="https://doi.org/10.1097/MCO.0000000000000714" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1097/MCO.0000000000000714</a>
  72. Verschueren SM, Bogaerts A, Delecluse C, Claessens AL, Haentjens P, Vanderschueren D, et al. The effects of whole-body vibration training and vitamin D supplementation on muscle strength, muscle mass, and bone density in institutionalized elderly women: a 6-month randomized, controlled trial. J Bone Miner Res 2011; 26: 42–9. doi: <a href="https://doi.org/10.1002/jbmr" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/jbmr</a>
  73. Gyergyek, A, Rotovnik Kozjek N, Klen, J. Monitoring the effect of perioperative nutritional care on body composition and functional status in patients with carcinoma of gastrointestinal and hepatobiliary system and pancreas. Radiol Oncol 2023; 57: 371–9. doi: <a href="https://doi.org/10.2478/raon-2023-0028" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.2478/raon-2023-0028</a>
DOI: https://doi.org/10.2478/raon-2024-0011 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 1 - 8
Submitted on: Nov 2, 2023
Accepted on: Dec 4, 2023
Published on: Feb 21, 2024
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year

© 2024 Mihaela Jurdana, Maja Cemazar, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.